Koscik, Timothy R. http://orcid.org/0000-0002-2551-8127
van der Plas, Ellen http://orcid.org/0000-0002-7490-6636
Gutmann, Laurie
Cumming, Sarah A. http://orcid.org/0000-0002-0201-3660
Monckton, Darren G.
Magnotta, Vincent
Shields, Richard K.
Nopoulos, Peggy C.
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (NS094387)
Article History
Received: 30 July 2020
Accepted: 15 February 2021
First Online: 1 March 2021
Competing interests
: DGM has been a scientific consultant and/or received an honoraria/stock options from AMO Pharma, Biogen Idec, Charles River, LoQus23, Small Molecule RNA, Triplet Therapeutics and Vertex Pharmaceuticals and had research contracts with AMO Pharma and Vertex Pharmaceuticals. DGM has received research grants/contracts from the European Union, CHDI, European Huntington Disease Network, Huntington Disease Society of America, National Institute of Health, Muscular Dystrophy UK and the Myotonic Dystrophy Support Group. DGM is on the Scientific Advisory Board of Myotonic (formerly the Myotonic Dystrophy Foundation) and EuroDyMA (European <i>Dystrophia Myotonica</i> Association), is a scientific advisor to the Myotonic Dystrophy Support Group and is a vice president of Muscular Dystrophy UK. TRK, EvdP, LG, SAC, VM, RKS, and PCN report no competing interest.